AMCP Studies Highlight Workplace Costs of Skin Care

October 21st 2021, 4:17pm


Studies presented at Academy of Managed Care Pharmacy Nexus 2021 elucidated costs of skin treatment for workers in terms of recovery time taken and percentage of salary.

Ixekizumab Improves Retention vs Secukinumab in Patients With Psoriasis

October 20th 2021, 7:50pm


Biologic-experienced patients with psoriasis exhibited significantly improved treatment adherence and lower discontinuation, nonpersistence, and switching rates over 18 months when prescribed ixekizumab vs secukinumab.

Evaluating Treatment Goals, Preferences in Parents and Young Patients With Psoriasis

October 15th 2021, 1:00pm


Pediatric populations, young adults, and parents all identified differing goals and preferences of treatment for psoriasis, with the most important treatment goals overall cited as lesion prevention and reduction.

Novel Calcipotriene, Betamethasone Dipropionate Cream Linked With Improved Outcomes and QOL in Psoriasis

October 13th 2021, 4:00pm


A novel formulation of calcipotriene (CAL), betamethasone dipropionate (BDP) cream was found to be more effective, provide superior quality of life, and safe in patients with psoriasis, compared with standard CAL/BDP topical suspension/gel.

Evaluating Common Conditions That Precede Psoriatic Arthritis Diagnosis

October 9th 2021, 4:30pm


Patients with psoriatic arthritis (PsA) were found to be more likely to report musculoskeletal symptoms and dermatologic issues prior to initial PsA diagnosis.

Brodalumab May Enhance Skin Clearance, QOL vs Ustekinumab for Psoriasis

October 6th 2021, 6:44pm


Patients with moderate to severe psoriasis were shown to achieve and maintain higher levels of complete skin clearance and quality of life when treated with brodalumab vs ustekinumab, regardless of the presence of lifestyle risk factors.

High Rate of Secukinumab Retention Shown Long Term in Patients With Psoriasis

October 1st 2021, 5:30pm


Secukinumab was associated with a high rate of short- and long-term drug survival in the treatment of patients with psoriasis, with factors such as obesity and prior biologic use linked to discontinuation of use.

Positive Fecal Immunochemistry Test May Increase Risk of Psoriasis

September 29th 2021, 4:50pm


Patients with a positive fecal immunochemistry test (FIT) were shown to be at significantly greater risk of developing psoriasis than those with FIT-negative tests.

Smoking, Periodontitis Linked With Increased Risk of Psoriasis

September 25th 2021, 2:00pm


Patients with periodontitis had a potential increased risk of developing psoriasis, particularly those who smoked.

Body Surface Area May Predict Risk of Psoriatic Arthritis in Patients With Psoriasis

September 22nd 2021, 3:41pm


Greater body surface area was shown to correlate with an increased risk of psoriatic arthritis development in patients with psoriasis, with obesity and depression also identified as risk factors.